Cargando…

Study of matrix metalloproteinases and their inhibitors in breast cancer

An immunohistochemical study was performed using tissue microarrays and specific antibodies against matrix metalloproteinases (MMPs) 1, 2, 7, 9, 11, 13, 14, and their tisullar inhibitors (TIMPs) 1, 2, and 3. More than 2600 determinations on cancer specimens from 131 patients with primary ductal inva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vizoso, F J, González, L O, Corte, M D, Rodríguez, J C, Vázquez, J, Lamelas, M L, Junquera, S, Merino, A M, García-Muñiz, J L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360108/ https://www.ncbi.nlm.nih.gov/pubmed/17342087 http://dx.doi.org/10.1038/sj.bjc.6603666

Ejemplares similares

Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse
por: González, L O, et al.
Publicado: (2007)

Study of matrix metalloproteinases and their inhibitors in prostate cancer
por: Escaff, S, et al.
Publicado: (2010)

Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors
por: Gonzalez, Luis O, et al.
Publicado: (2008)

Impact of CD68/(CD3+CD20) Ratio at the Invasive Front of Primary Tumors on Distant Metastasis Development in Breast Cancer
por: Eiró, Noemí, et al.
Publicado: (2012)

Matrix Metalloproteinases and Bladder Cancer: What is New?
por: Rodriguez Faba, O., et al.
Publicado: (2012)

Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure
por: Gialafos, Elias J., et al.
Publicado: (2008)

The Effect of Autologous Platelet-Rich Gel on the Dynamic Changes of the Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in the Diabetic Chronic Refractory Cutaneous Ulcers
por: Li, Lan, et al.
Publicado: (2015)

Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis
por: Jones, Tiffanie K., et al.
Publicado: (2022)

Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
por: Zhang, Yongxiang, et al.
Publicado: (2020)

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996)

Expression and prognostic significance of lysozyme in male breast cancer
por: Serra, Carlos, et al.
Publicado: (2002)

Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls
por: Luckman, Steven P., et al.
Publicado: (2011)

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours
por: Wall, L, et al.
Publicado: (2004)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
por: Cabral-Pacheco, Griselda A, et al.
Publicado: (2020)

Elevation of Matrix Metalloproteinases in Different Areas of Ascending Aortic Aneurysms in Patients with Bicuspid and Tricuspid Aortic Valves
por: Mohamed, Salah A., et al.
Publicado: (2012)

Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis
por: Ally, Mahmood M. T. M., et al.
Publicado: (2013)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
por: Remacle, A. G., et al.
Publicado: (1998)

Effects of Expression of Matrix Metalloproteinases and Discoidin Domain Receptors in Ligamentum Flavum Fibrosis in Patients with Degenerative Lumbar Canal Stenosis
por: Torun, Yusuf Mansur, et al.
Publicado: (2023)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Rheumatoid Factor Positivity Is Associated with Increased Joint Destruction and Upregulation of Matrix Metalloproteinase 9 and Cathepsin K Gene Expression in the Peripheral Blood in Rheumatoid Arthritic Patients Treated with Methotrexate
por: Tchetina, Elena V., et al.
Publicado: (2013)

Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis
por: González-Reyes, Salomé, et al.
Publicado: (2010)

Evaluation of serum neopterin, periostin, Tenascin‐C, tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-2 levels in obese pregnant women
por: Melekoğlu, Rauf, et al.
Publicado: (2022)

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
por: Parsons, M F C, et al.
Publicado: (2008)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2010)

Towards third generation matrix metalloproteinase inhibitors for cancer therapy
por: Overall, C M, et al.
Publicado: (2006)

Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study
por: Soni, Kapil, et al.
Publicado: (2021)

The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis
por: Ruiz-Padilla, A. J., et al.
Publicado: (2016)

The −174G/C and −572G/C Interleukin 6 Promoter Gene Polymorphisms in Mexican Patients with Rheumatoid Arthritis: A Case-Control Study
por: Zavaleta-Muñiz, S. A., et al.
Publicado: (2013)

The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors
por: Das, Nabangshu, et al.
Publicado: (2020)

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
por: Flågeng, M Hauglid, et al.
Publicado: (2009)

Mammographic Density and Matrix Metalloproteinases in Breast Tissue
por: Steude, Jana S., et al.
Publicado: (2009)

Role of Matrix Metalloproteinase-9 in Neonatal Hypoxic-Ischemic Encephalopathy
por: Salah, Mohab M., et al.
Publicado: (2019)

Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens
por: Karli, Sapir, et al.
Publicado: (2018)

Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma
por: Vázquez-Lorente, Héctor, et al.
Publicado: (2022)

The level of ratio between matrix metalloproteinase-1 (MMP-1) and tissue inhibitor matrix metalloproteinase-1 (TIMP-1) after prolotherapy intervention and the functional outcome in patient with frozen shoulder: A randomized controlled trial
por: Sam, Nuralam, et al.
Publicado: (2023)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_egued2u1u8a68c29nj921i572v